# Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

> **NCT04256759** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 9 (actual)

## Conditions studied

- Pruritus

## Interventions

- **DRUG:** Dupilumab 300Mg Solution for Injection

## Key facts

- **NCT ID:** NCT04256759
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-09-06
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256759, "Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04256759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*